Paul Reider
Corporate Officer/Principal en COHERUS BIOSCIENCES, INC. .
Fortuna: 194 252 $ al 31/03/2024
Perfil
Paul Reider is a member of the Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. He is also the Chief Commercial Officer at Coherus BioSciences, Inc. starting in 2022.
Previously, he worked as the Vice President of Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021.
He also held a position as the General Manager at Ipsen Biopharmaceuticals Canada, Inc. Mr. Reider completed his undergraduate degree and MBA at Bowling Green State University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 09/04/2024 | 81 277 ( 0.07% ) | 194 252 $ | 31/03/2024 |
Cargos activos de Paul Reider
| Empresas | Cargo | Inicio |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Paul Reider.
| Empresas | Cargo | Fin |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 01/01/2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - |
Formación de Paul Reider.
| Bowling Green State University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
- Bolsa de valores
- Insiders
- Paul Reider
